Catalyst Wire Dossier Catalyst Wire Dossier

Deforolimus

ridaforolimus · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Deforolimus, covering 2015-02-13 to 2015-08-27. Get the full timeline:

Most recent: Clinical Trial Update: Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) [Phase 2]

See pricing